Boston Immune Technologies & Therapeutics

0 followers

‌

BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.

Industries

Therapeutics, Biotechnology

Headquarters

Winchester, United States

Employees

1-10

Links

Org chart

Russell LaMontagne

CEO

Russell LaMontagne

Collapse

David Brooks

Chief Medical Officer

VP of Manufacturing

Finance Director

Director of Legal

Director of Preclinical Development

Mohammad Razvi

Director of Clinical Operations & Development

Teams

This company has no teams yet

Similar companies

Heligenics

1 follower

Amgen

219 followers

Garuda Therapeutics

4 followers

Thermo Fisher Scientific

169 followers

Genentech

155 followers

Gilead Sciences

130 followers

Biogen

116 followers

Regeneron

97 followers

Illumina

69 followers

Vertex Pharmaceuticals

60 followers

Agilent Technologies

66 followers

Explore companies

��������